Scott Wasserman

Title: Scott Wasserman: Innovator in Cardiac Therapy

Introduction

Scott Wasserman is a notable inventor based in Newbury Park, California. He has made significant contributions to the field of cardiac therapy, particularly in the treatment of heart failure. His innovative approach combines different therapeutic agents to enhance patient outcomes.

Latest Patents

Wasserman holds a patent for a groundbreaking invention titled "Combination therapy of cardiac myosin activator and sinus node If current inhibitor." This patent discloses combination therapies for treating heart failure using a cardiac myosin activator, such as omecamtiv mecarbil, alongside a sinus node If current inhibitor, such as ivabradine. The patent also includes compositions that comprise both a cardiac myosin activator and a sinus node If current inhibitor.

Career Highlights

Scott Wasserman is associated with Amgen Inc., a leading biotechnology company known for its innovative therapies. His work at Amgen has allowed him to focus on developing advanced treatments for cardiovascular diseases. His dedication to research and development has positioned him as a key player in the field.

Collaborations

Wasserman collaborates with esteemed colleagues, including Robert Andrew Donald Scott and Joyce Chi Chan. These partnerships enhance the research and development process, fostering innovation in cardiac therapies.

Conclusion

Scott Wasserman's contributions to cardiac therapy through his patent and work at Amgen Inc. highlight his commitment to improving heart failure treatments. His innovative approaches and collaborations with other experts in the field continue to pave the way for advancements in medical science.